GlassScriptPhysician profile
Larry Liriano-Espinal
NPI 1932514833
$4,167.43
in general payments reported to CMS, 2019-2025
31 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $123 · 2021: $145 · 2022: $146 · 2023: $669 · 2024: $1,248 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.18 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $506.63 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $354.18 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $316.71 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $306.47 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $293.58 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $268.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $253.42 | 2023-2025 | |
| Insulet Corporation | $226.83 | 2024-2025 | Omnipod |
| Kyowa Kirin, INC. | $212.77 | 2024-2025 | Crysvita |
| Lilly USA, LLC | $200.61 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Tandem Diabetes Care, INC. | $139.30 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $138.90 | 2023-2025 | Isturisa, Signifor Lar |
| Impel Pharmaceuticals INC. | $94.87 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $93.62 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $90.96 | 2025 | Yorvipath |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.05 | 2023-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $67.75 | 2023-2025 | |
| Ionis Pharmaceuticals, INC. | $66.65 | 2025 | Tryngolza |
| Mannkind Corporation | $63.16 | 2025 | |
| Radius Health, INC. | $56.29 | 2025 | |
| Glaxosmithkline, LLC. | $53.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $53.19 | 2021 | |
| Abbvie INC. | $38.38 | 2021 | |
| Pfizer INC. | $33.92 | 2022-2023 | |
| Beta Bionics, INC. | $31.04 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $29.39 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.11 | 2025 | Jardiance |
| Halozyme INC | $20.32 | 2023 | |
| Sequel Med Tech, LLC | $19.43 | 2025 | Twiist |
| Ibsa Pharma INC. | $18.90 | 2025 | Tirosint, Licart, Flector |
| Embecta Corp. | $15.72 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Liriano-Espinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.